◈ PeptideAtlasCONNECTED KNOWLEDGE
THE PEPTIDE REFERENCE

Tesamorelin

Tesamorelin is approved for excess abdominal visceral fat in adults with HIV-associated lipodystrophy. It stimulates the GH–IGF-1 axis and is generally weight neutral; use for ordinary obesity, bodybuilding or anti-aging is outside that approved indication.

Also known as Egrifta · Egrifta SV · Egrifta WR · Tesamorelin (off-label)

Approved medicine · see jurisdictionEstablished clinical evidenceDigestive & metabolismHormones
AI-assisted source review · 2026-10-272 cited sources2 min read

At a glance

ProductsEgrifta SV; Egrifta WR
TargetPituitary GHRH receptor
Approved scopeAdult HIV-associated lipodystrophy
Main measured outcomeVisceral abdominal fat
Key monitoringIGF-1 and glucose

Overview

Egrifta formulations contain tesamorelin, a growth hormone-releasing factor analog. The approved population has HIV-associated lipodystrophy with excess abdominal fat, which differs from generalized obesity and from isolated low growth-hormone measurements. Trials measured visceral adipose tissue, not merely body weight. This profile intentionally combines the reference catalog’s standard and off-label tesamorelin listings because they concern the same active molecule. Keeping them together makes the boundary clear: approval of the HIV indication does not establish a favorable benefit-risk balance for general wellness, athletic physique goals or treatment of aging.

Supporting sources [1] [2]

How it works

Tesamorelin binds pituitary GHRH receptors and increases endogenous growth-hormone release, leading to increased IGF-1 and downstream metabolic effects. It therefore requires a responsive hypothalamic-pituitary axis and differs from injecting recombinant GH directly. Visceral-fat reduction can occur without meaningful overall weight loss. Stimulation of this hormonal pathway also explains concerns about glucose tolerance, fluid retention and exposure of susceptible tissues to growth signals.

Supporting sources [1] [2]

Approved versus off-label use

U.S. labeling limits use to reducing excess abdominal fat in adults with HIV-associated lipodystrophy and states that tesamorelin is not indicated for weight-loss management. Its long-term cardiovascular safety has not been established.

Supporting sources [1]

What randomized trials demonstrated

A placebo-controlled trial showed reductions in visceral adipose tissue and improvements in body-image distress. During the extension, visceral-fat benefit was maintained with continued treatment and rapidly lost after switching to placebo. A response therefore does not imply permanent remodeling.

Supporting sources [2]

Growth-factor and metabolic risks

Elevated IGF-1, glucose intolerance or diabetes, fluid retention, joint symptoms, carpal-tunnel-type symptoms and hypersensitivity are important concerns. Active malignancy, pregnancy and disruption of the hypothalamic-pituitary axis are contraindications.

Supporting sources [1]

What a meaningful response includes

IGF-1 and glucose require assessment in addition to body composition. A change in abdominal appearance should be balanced against metabolic adverse effects and the reason for treatment. Egrifta formulations have different preparation characteristics and are not interchangeable solely by volume.

Supporting sources [1]

Why the off-label listing is merged

The molecule is the same when marketed for wellness, but the patient population and evidence are different. Combining the records avoids duplicate knowledge and makes it possible to explain approved HIV-related care and unapproved general-wellness claims in one evidence-based account.

Supporting sources [1] [2]

Common questions

Does tesamorelin treat ordinary obesity? Its FDA indication is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. That does not establish general obesity treatment.

Is the fat reduction permanent? Extension studies found that visceral fat tended to return after treatment stopped. The decision to continue therefore involves both demonstrated response and ongoing metabolic and growth-factor safety assessment.

Supporting sources [1] [2]

Reading this profile

Jurisdiction: United States — FDA-approved prescription medicine; indication and formulation restrictions apply.. Molecular class: Growth hormone-releasing hormone analog peptide.

This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.

Sources & references

Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.

  1. DailyMed: Egrifta current prescribing information ↗
    Regulatory source · Checked 2026-10-27
  2. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. ↗
    Original research · Checked 2026-10-27
CONTINUE EXPLORING

Related profiles

CJC-1295 ↗CJC-1295 is an investigational growth hormone-releasing hormone analog designed to prolong stimulation of the GH–IGF-1 axis. Small human studies established sustained hormonal responses. They did not establish improvements in longevity, athletic recovery, or meaningful muscle function, and products marketed without DAC are not equivalent to the studied molecule.GHRP-2 ↗GHRP-2 is a growth hormone secretagogue that also affects appetite and other endocrine pathways. Human studies establish GH release and include diagnostic endocrine testing. They do not establish routine bodybuilding or anti-aging benefit, and FDA identifies safety concerns for compounded injectable and nasal preparations.GHRP-6 ↗GHRP-6 is an experimental peptide that stimulates growth hormone through the ghrelin-receptor system. Small human studies demonstrate endocrine responses, while evidence for meaningful muscle, recovery, or longevity outcomes remains inadequate. FDA highlights limited safety information, effects on cortisol, and impaired insulin sensitivity.Hexarelin ↗Hexarelin is an investigational growth hormone-releasing peptide with additional experimental cardiovascular effects. Small human studies show strong GH responses, while cell and animal work examines receptors such as CD36. These findings do not establish a safe, effective treatment for muscle gain, heart disease, or aging.Ipamorelin ↗Ipamorelin is an investigational ghrelin-receptor agonist that stimulates growth hormone release. It has early human pharmacology data and was studied for postoperative bowel recovery, without significant efficacy in a small randomized trial. Claims for muscle gain, fat loss, and anti-aging are not established therapeutic indications.MK-677 (ibutamoren) ↗Ibutamoren is a nonpeptide drug candidate that stimulates growth hormone and IGF-1 through the ghrelin receptor. Human trials have examined aging, muscle loss, Alzheimer disease, and pediatric GH deficiency. Hormone and lean-mass increases have not consistently translated into functional benefit, and metabolic and heart-failure concerns remain.